BPC-157 in 2026: what changed, what hasn’t, and what to expect

HHS signaled, FDA has not yet acted. Here is where BPC-157 sits as of April 2026.

TL;DR

• BPC-157 is currently classified by the FDA as a Category 2 peptide and is not available from 503A compounding pharmacies.
• In February 2026, HHS announced intent to review and potentially reclassify several Category 2 peptides, including BPC-157.
• A formal FDA Federal Register notice would be the next required step. As of April 2026, that notice has not been issued.

What it is

The FDA’s compounding framework sorts substances proposed for use in 503A compounding into categories. Category 1 substances are permitted; Category 2 substances have been flagged for additional review and are not currently permitted in 503A compounding pending that review. BPC-157 — a synthetic peptide derived from a fragment of human gastric juice — was placed in Category 2 in 2023. The February 2026 HHS announcement signaled intent to revisit several of these Category 2 placements, BPC-157 among them.

How it works

A regulatory reclassification follows a defined sequence. Step one: HHS or FDA issues a public statement of intent. Step two: FDA opens a formal review and a public comment period through the Federal Register. Step three: the Pharmacy Compounding Advisory Committee (PCAC) typically meets to review evidence. Step four: FDA issues a final Federal Register notice formally moving the substance from one category to the other. The February 2026 HHS announcement put BPC-157 at step one. The next visible step is the Federal Register opening — until that publishes, the operational status has not changed.

Who asks about it

People come to this question after seeing headlines that BPC-157 is “legal again” or “back on the market.” The clean way to read those headlines is: HHS signaled, FDA has not yet acted, and the legal status of the molecule has not changed for compounding pharmacies as of today.

What the research says

The Federal Register is the official daily publication of the U.S. government and is the authoritative source for FDA rule changes (Federal Register). The FDA also maintains a public list of bulk drug substance nominations under 503A, with status notes for each substance (FDA 503A Bulks List). Patients and clinicians watching this space should bookmark both — they update faster than secondary commentary.

What to know before considering it

Until the FDA formally reclassifies BPC-157, it is not available through state-licensed 503A compounding pharmacies. Research-use-only suppliers operate outside the licensed channel and have been associated with documented purity, sterility, and labeling issues. Halftime Health does not source through those channels. If and when the regulatory status changes, the change will be reflected in our formulary and described plainly in this blog.

The Halftime POV

The honest version of the BPC-157 story in 2026 is “stay tuned.” HHS said the right things; FDA has not yet finished the process. We treat the regulatory status as binary — available through licensed channels or not — and we report the status as it actually is, not as it might be by the end of the year.

Related reading:

• BPC-157: what this body protection compound is
• BPC-157 and the Category 2 question
• Category 1 vs Category 2 peptides: the access framework

FAQ

Q: Is BPC-157 legal to buy in 2026? A: BPC-157 is currently FDA Category 2, which means it is not available from 503A compounding pharmacies. The February 2026 HHS announcement signaled intent to revisit Category 2 peptides, but a formal FDA Federal Register notice has not been issued.

Q: Did BPC-157 get reclassified? A: Not yet through formal Federal Register action. HHS announced intent to review Category 2 peptides in February 2026, and FDA continues its review process. The status is being watched closely; updates will follow the official notice.

Q: Where can I get BPC-157? A: Until the FDA changes its current position, BPC-157 is not legally available through 503A compounding pharmacies. Research-use-only sources are not legal channels for human use and carry quality risks documented in the literature.

Q: When will the change happen, if it happens? A: A typical Federal Register process takes several months from intent to final rule. PCAC meeting timing and public comment windows shape the schedule.

Disclaimer

As of April 2026, several peptides discussed in this article — including BPC-157 — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Federal Register — official daily publication of U.S. government rules and notices
• Bulk Drug Substances Nominations Received for Use in Compounding Under Section 503A — FDA, 2024

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.